-
1
-
-
0015861556
-
Oestrogen-receptor interaction
-
Jensen, E. V., DeSombre, E. R. Oestrogen-receptor interaction. Science 182, 126-134 (1973).
-
(1973)
Science
, vol.182
, pp. 126-134
-
-
Jensen, E.V.1
DeSombre, E.R.2
-
2
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
-
3
-
-
0032569831
-
Tamoxifen in the treatment of breast cancer
-
Osborne, C. K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339, 1609-1618 (1998).
-
(1998)
N. Engl. J. Med.
, vol.339
, pp. 1609-1618
-
-
Osborne, C.K.1
-
4
-
-
73949090721
-
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
-
Dawood, S., Broglio, K., Buzdar, A. U., Hortobagyi, G. N., Giordano, S. H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 28, 92-98 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 92-98
-
-
Dawood, S.1
Broglio, K.2
Buzdar, A.U.3
Hortobagyi, G.N.4
Giordano, S.H.5
-
5
-
-
84885735554
-
Mutational landscape and significance across 12 major cancer types
-
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
-
(2013)
Nature
, vol.502
, pp. 333-339
-
-
Kandoth, C.1
-
6
-
-
84861576201
-
The landscape of cancer genes and mutational processes in breast cancer
-
Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
-
(2012)
Nature
, vol.486
, pp. 400-404
-
-
Stephens, P.J.1
-
7
-
-
84885435345
-
Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive HER2-negative advanced breast cancer: Results from BOLERO-2 [abstract]
-
Hortobagyi, G. N. et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2 [abstract]. J. Clin. Oncol. 31 (Suppl.), LBA509 (2013).
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. LBA509
-
-
Hortobagyi, G.N.1
-
8
-
-
84973385116
-
Translational studies within the TAMRAD randomized GINECO trial: Evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer
-
Treilleux, I. et al. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Ann. Oncol. 26, 120-125 (2015).
-
(2015)
Ann. Oncol.
, vol.26
, pp. 120-125
-
-
Treilleux, I.1
-
9
-
-
84862526929
-
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
-
Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012).
-
(2012)
Nature
, vol.486
, pp. 395-399
-
-
Shah, S.P.1
-
10
-
-
84857568955
-
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer
-
Amir, E. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 30, 587-592 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 587-592
-
-
Amir, E.1
-
11
-
-
84863116159
-
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumours
-
Niikura, N. et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumours. J. Clin. Oncol. 30, 593-599 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 593-599
-
-
Niikura, N.1
-
12
-
-
84888391516
-
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
-
Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439-1445 (2013).
-
(2013)
Nat. Genet.
, vol.45
, pp. 1439-1445
-
-
Toy, W.1
-
13
-
-
84888381937
-
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
-
Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446-1451 (2013).
-
(2013)
Nat. Genet.
, vol.45
, pp. 1446-1451
-
-
Robinson, D.R.1
-
14
-
-
84927582380
-
Genomic and immune characterization of metastatic breast cancer (mBC): And ancillary study of the SAFIR01 & MOSCATO trials [abstract]
-
Arnedos, M. et al. Genomic and immune characterization of metastatic breast cancer (mBC): And ancillary study of the SAFIR01 & MOSCATO trials [abstract]. Ann. Oncol. 25, a351O (2014).
-
(2014)
Ann. Oncol.
, vol.25
, pp. a351O
-
-
Arnedos, M.1
-
15
-
-
84948381310
-
Enriching phase I trials with molecular alterations: Interim analysis of 708 patients enrolled in the MOSCATO 01 trial [abstract]
-
Paris, France, aO3.7
-
Massard, C. et al. Enriching phase I trials with molecular alterations: Interim analysis of 708 patients enrolled in the MOSCATO 01 trial [abstract]. 13th International Congress on Targeted Anticancer Therapies, Paris, France, aO3.7 (2015).
-
(2015)
13th International Congress on Targeted Anticancer Therapies
-
-
Massard, C.1
-
16
-
-
84887431012
-
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
-
Lord, C. J., Ashworth, A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 19, 1381-1388 (2013).
-
(2013)
Nat. Med.
, vol.19
, pp. 1381-1388
-
-
Lord, C.J.1
Ashworth, A.2
-
17
-
-
84962115811
-
Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003
-
Wagle, N. et al. Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003. Cancer Res. 75, PD3-PD5 (2015).
-
(2015)
Cancer Res.
, vol.75
, pp. PD3-PD5
-
-
Wagle, N.1
-
18
-
-
77954526150
-
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of oestrogen and progesterone receptors in breast cancer
-
Hammond, M. E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of oestrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784-2795 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 2784-2795
-
-
Hammond, M.E.1
-
19
-
-
84890254448
-
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
-
Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997-4013 (2013).
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 3997-4013
-
-
Wolff, A.C.1
-
20
-
-
19944422061
-
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
-
Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
-
(2004)
N. Engl. J. Med.
, vol.351
, pp. 2817-2826
-
-
Paik, S.1
-
21
-
-
0037137519
-
A gene-expression signature as a predictor of survival in breast cancer
-
van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
-
(2002)
N. Engl. J. Med.
, vol.347
, pp. 1999-2009
-
-
Van De Vijver, M.J.1
-
22
-
-
0037478605
-
Repeated observation of breast tumour subtypes in independent gene expression data sets
-
Sorlie, T. et al. Repeated observation of breast tumour subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
-
(2003)
Proc. Natl Acad. Sci. USA
, vol.100
, pp. 8418-8423
-
-
Sorlie, T.1
-
23
-
-
84871820669
-
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in oestrogen receptor positive breast cancer
-
Loi, S. et al. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in oestrogen receptor positive breast cancer. PLoS ONE 8, e53292 (2013).
-
(2013)
PLoS ONE
, vol.8
, pp. e53292
-
-
Loi, S.1
-
24
-
-
84875723816
-
A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer [abstract]
-
Balko, J. M. et al. A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer [abstract]. J. Clin. Oncol. 30 (Suppl.), a1024 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. a1024
-
-
Balko, J.M.1
-
25
-
-
84896730857
-
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER)
-
Andre, F. et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 15, 267-274 (2014).
-
(2014)
Lancet Oncol.
, vol.15
, pp. 267-274
-
-
Andre, F.1
-
26
-
-
84866736379
-
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer
-
Arnedos, M. et al. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. Eur. J. Cancer 48, 2293-2299 (2012).
-
(2012)
Eur. J. Cancer
, vol.48
, pp. 2293-2299
-
-
Arnedos, M.1
-
27
-
-
84902148239
-
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumour samples to guide precision cancer medicine
-
Van Allen, E. M. et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumour samples to guide precision cancer medicine. Nat. Med. 20, 682-688 (2014).
-
(2014)
Nat. Med.
, vol.20
, pp. 682-688
-
-
Van Allen, E.M.1
-
28
-
-
84901664854
-
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
-
Watkins, J. A., Irshad, S., Grigoriadis, A., Tutt, A. N. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 16, 211 (2014).
-
(2014)
Breast Cancer Res.
, vol.16
, pp. 211
-
-
Watkins, J.A.1
Irshad, S.2
Grigoriadis, A.3
Tutt, A.N.4
-
29
-
-
84875520648
-
Analysis of circulating tumour DNA to monitor metastatic breast cancer
-
Dawson, S. J. et al. Analysis of circulating tumour DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013).
-
(2013)
N. Engl. J. Med.
, vol.368
, pp. 1199-1209
-
-
Dawson, S.J.1
-
30
-
-
84877579861
-
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
-
Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).
-
(2013)
Nature
, vol.497
, pp. 108-112
-
-
Murtaza, M.1
-
31
-
-
84859187259
-
Systematic identification of genomic markers of drug sensitivity in cancer cells
-
Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
-
(2012)
Nature
, vol.483
, pp. 570-575
-
-
Garnett, M.J.1
-
32
-
-
84877028141
-
Comprehensive molecular portraits of human breast tumours
-
Cancer Genome Atlas N.
-
Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
-
(2012)
Nature
, vol.490
, pp. 61-70
-
-
-
33
-
-
84863338519
-
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harbouring PIK3CA mutations
-
Janku, F. et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harbouring PIK3CA mutations. J. Clin. Oncol. 30, 777-782 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 777-782
-
-
Janku, F.1
-
34
-
-
84879859652
-
Targeting FGFR with dovitinib (TKI258): Preclinical and clinical data in breast cancer
-
Andre, F. et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin. Cancer Res. 19, 3693-3702 (2013).
-
(2013)
Clin. Cancer Res.
, vol.19
, pp. 3693-3702
-
-
Andre, F.1
-
35
-
-
84925408760
-
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumours
-
Soria, J. C. et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumours. Ann. Oncol. 25, 2244-2251 (2014).
-
(2014)
Ann. Oncol.
, vol.25
, pp. 2244-2251
-
-
Soria, J.C.1
-
36
-
-
84873918443
-
Activating HER2 mutations in HER2 gene amplification negative breast cancer
-
Bose, R. et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3, 224-237 (2013).
-
(2013)
Cancer Discov.
, vol.3
, pp. 224-237
-
-
Bose, R.1
-
37
-
-
84922369296
-
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study
-
Finn, R. S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25-35 (2015).
-
(2015)
Lancet Oncol.
, vol.16
, pp. 25-35
-
-
Finn, R.S.1
-
38
-
-
60749109846
-
Cell cycle CDKs and cancer: A changing paradigm
-
Malumbres, M., Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153-166 (2009).
-
(2009)
Nat. Rev. Cancer
, vol.9
, pp. 153-166
-
-
Malumbres, M.1
Barbacid, M.2
-
39
-
-
78650510609
-
MTOR: From growth signal integration to cancer, diabetes and ageing
-
Zoncu, R., Efeyan, A., Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell. Biol. 12, 21-35 (2011).
-
(2011)
Nat. Rev. Mol. Cell. Biol.
, vol.12
, pp. 21-35
-
-
Zoncu, R.1
Efeyan, A.2
Sabatini, D.M.3
-
40
-
-
84948382242
-
A first-in-human phase I study to evaluate the oral selective oestrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with oestrogen receptor+ HER2-advanced/metastatic breast cancer
-
CT231
-
Dickler, M. et al. A first-in-human phase I study to evaluate the oral selective oestrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with oestrogen receptor+ HER2-, advanced/metastatic breast cancer. AACR [abstract CT231] (2015).
-
(2015)
AACR
-
-
Dickler, M.1
-
41
-
-
84925500147
-
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor
-
Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature 518, 240-244 (2015).
-
(2015)
Nature
, vol.518
, pp. 240-244
-
-
Juric, D.1
-
42
-
-
84882837534
-
Signatures of mutational processes in human cancer
-
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
-
(2013)
Nature
, vol.500
, pp. 415-421
-
-
Alexandrov, L.B.1
-
43
-
-
84903390239
-
APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumour development
-
Henderson, S., Chakravarthy, A., Su, X., Boshoff, C., Fenton, T. R. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumour development. Cell Rep. 7, 1833-1841 (2014).
-
(2014)
Cell Rep.
, vol.7
, pp. 1833-1841
-
-
Henderson, S.1
Chakravarthy, A.2
Su, X.3
Boshoff, C.4
Fenton, T.R.5
-
44
-
-
84962048442
-
ARIEL2: A phase 2 study to prospectively identify ovarian cancer patients likely to respond to rucaparib [abstract]
-
Swisher, E. et al. ARIEL2: A phase 2 study to prospectively identify ovarian cancer patients likely to respond to rucaparib [abstract]. 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, a215 (2014).
-
(2014)
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
, pp. a215
-
-
Swisher, E.1
-
45
-
-
77955019276
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial
-
Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244 (2010).
-
(2010)
Lancet
, vol.376
, pp. 235-244
-
-
Tutt, A.1
-
46
-
-
84919921642
-
Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents
-
Cui, Y., Palii, S. S., Innes, C. L., Paules, R. S. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents. Cell Cycle 13, 541-550 (2014).
-
(2014)
Cell Cycle
, vol.13
, pp. 541-550
-
-
Cui, Y.1
Palii, S.S.2
Innes, C.L.3
Paules, R.S.4
-
47
-
-
84925664415
-
ATM and ATR as therapeutic targets in cancer
-
Weber, A. M., Ryan, A. J. ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther. 149, 124-138 (2015).
-
(2015)
Pharmacol. Ther.
, vol.149
, pp. 124-138
-
-
Weber, A.M.1
Ryan, A.J.2
-
48
-
-
84933575890
-
Predicting anthracycline benefit: TOP2A and CEP17-not only but also
-
Bartlett, J. M. et al. Predicting anthracycline benefit: TOP2A and CEP17-not only but also. J. Clin. Oncol. 33, 1680-1687 (2015).
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 1680-1687
-
-
Bartlett, J.M.1
-
49
-
-
84937961692
-
A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer [abstract]
-
Nanda, R. et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer [abstract]. Cancer Res. 75, S1-09 (2015).
-
(2015)
Cancer Res.
, vol.75
, pp. S1-09
-
-
Nanda, R.1
-
50
-
-
84918828514
-
Genetic basis for clinical response to CTLA-4 blockade in melanoma
-
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
-
(2014)
N. Engl. J. Med.
, vol.371
, pp. 2189-2199
-
-
Snyder, A.1
-
51
-
-
0035893563
-
Immune escape of melanoma: First evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway
-
Seliger, B. et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 61, 8647-8650 (2001).
-
(2001)
Cancer Res.
, vol.61
, pp. 8647-8650
-
-
Seliger, B.1
-
52
-
-
84920956732
-
PD-1 blockade induces responses by inhibiting adaptive immune resistance
-
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
-
(2014)
Nature
, vol.515
, pp. 568-571
-
-
Tumeh, P.C.1
-
53
-
-
84863936531
-
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: A pooled analysis
-
Ignatiadis, M. et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J. Clin. Oncol. 30, 1996-2004 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 1996-2004
-
-
Ignatiadis, M.1
-
54
-
-
84871356760
-
Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer
-
Vacchelli, E. et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Onco-immunology 1, 271-278 (2012).
-
(2012)
Onco-immunology
, vol.1
, pp. 271-278
-
-
Vacchelli, E.1
-
55
-
-
84856071447
-
Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumours
-
Bendell, J. C. et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumours. J. Clin. Oncol. 30, 282-290 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 282-290
-
-
Bendell, J.C.1
-
56
-
-
84880507665
-
Mutational heterogeneity in cancer and the search for new cancer-associated genes
-
Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
-
(2013)
Nature
, vol.499
, pp. 214-218
-
-
Lawrence, M.S.1
-
57
-
-
79955166265
-
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
-
Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
-
(2011)
Genome Biol.
, vol.12
, pp. R41
-
-
Mermel, C.H.1
-
58
-
-
58149112821
-
Functional copy-number alterations in cancer
-
Taylor, B. S. et al. Functional copy-number alterations in cancer. PLoS ONE 3, e3179 (2008).
-
(2008)
PLoS ONE
, vol.3
, pp. e3179
-
-
Taylor, B.S.1
-
59
-
-
84864598664
-
MuSiC: Identifying mutational significance in cancer genomes
-
Dees, N. D. et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 22, 1589-1598 (2012).
-
(2012)
Genome Res.
, vol.22
, pp. 1589-1598
-
-
Dees, N.D.1
-
60
-
-
84883799242
-
DrGaP: A powerful tool for identifying driver genes and pathways in cancer sequencing studies
-
Hua, X. et al. DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. Am. J. Hum. Genet. 93, 439-451 (2013).
-
(2013)
Am. J. Hum. Genet.
, vol.93
, pp. 439-451
-
-
Hua, X.1
-
61
-
-
84887032986
-
IntOGen-mutations identifies cancer drivers across tumour types
-
Gonzalez-Perez, A. et al. IntOGen-mutations identifies cancer drivers across tumour types. Nat. Methods 10, 1081-1082 (2013).
-
(2013)
Nat. Methods
, vol.10
, pp. 1081-1082
-
-
Gonzalez-Perez, A.1
-
62
-
-
84924279179
-
In silico prescription of anticancer drugs to cohorts of 28 tumour types reveals targeting opportunities
-
Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumour types reveals targeting opportunities. Cancer Cell 27, 382-396 (2015).
-
(2015)
Cancer Cell
, vol.27
, pp. 382-396
-
-
Rubio-Perez, C.1
-
63
-
-
84939503725
-
Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival
-
Suo, C. et al. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival. Bioinformatics https://dx.doi.org/10.1093/bioinformatics/btv164 (2015).
-
(2015)
Bioinformatics
-
-
Suo, C.1
-
64
-
-
84899992665
-
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial
-
Andre, F. et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 15, 580-591 (2014).
-
(2014)
Lancet Oncol.
, vol.15
, pp. 580-591
-
-
Andre, F.1
-
65
-
-
38849096990
-
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
-
Andre, F. et al. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann. Oncol. 19, 315-320 (2008).
-
(2008)
Ann. Oncol.
, vol.19
, pp. 315-320
-
-
Andre, F.1
-
66
-
-
84904724740
-
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in oestrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
-
Mayer, I. A. et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in oestrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 32, 1202-1209 (2014).
-
(2014)
J. Clin. Oncol.
, vol.32
, pp. 1202-1209
-
-
Mayer, I.A.1
-
67
-
-
84899785427
-
Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials
-
Fritsch, C. et al. Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther. 13, 1117-1129 (2014).
-
(2014)
Mol. Cancer Ther.
, vol.13
, pp. 1117-1129
-
-
Fritsch, C.1
-
68
-
-
84954518142
-
Phase I study of the PI3K inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer [abstract]
-
Janku, F. et al. Phase I study of the PI3K inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer [abstract]. Cancer Res. 74, PD5-5 (2014).
-
(2014)
Cancer Res.
, vol.74
, pp. PD5-5
-
-
Janku, F.1
-
69
-
-
84948383740
-
Combination of targetable gene alterations decreases anti-cancer drug treatment response in cell lines and patients [abstract P10]
-
Hinxton, Cambridge, UK
-
Fu, Y., Ferte, C., Soria, J. C., F., A., Lefebvre, C. Combination of targetable gene alterations decreases anti-cancer drug treatment response in cell lines and patients [abstract P10]. Cancer Pharmacogenomics and Targeted Therapies, Hinxton, Cambridge, UK (2014).
-
(2014)
Cancer Pharmacogenomics and Targeted Therapies
-
-
Fu, Y.1
Ferte, C.2
Soria, J.C.F.A.3
Lefebvre, C.4
-
70
-
-
84908406068
-
Does toxicity predict efficacy Insight into the mechanism of action of lapatinib
-
Fontanella, C. et al. Does toxicity predict efficacy Insight into the mechanism of action of lapatinib. J. Clin. Oncol. 32, 3458-3459 (2014).
-
(2014)
J. Clin. Oncol.
, vol.32
, pp. 3458-3459
-
-
Fontanella, C.1
-
71
-
-
84911926434
-
Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer
-
Baselga, J. et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J. Clin. Oncol. 32, 753-761 (2014).
-
(2014)
J. Clin. Oncol.
, vol.32
, pp. 753-761
-
-
Baselga, J.1
-
72
-
-
84903806146
-
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab-and trastuzumab-based therapy: An exploratory analysis of the TRYPHAENA study
-
Schneeweiss, A. et al. Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab-and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. Breast Cancer Res. 16, R73 (2014).
-
(2014)
Breast Cancer Res.
, vol.16
, pp. R73
-
-
Schneeweiss, A.1
-
73
-
-
84887478023
-
Tumour adaptation and resistance to RAF inhibitors
-
Lito, P., Rosen, N., Solit, D. B. Tumour adaptation and resistance to RAF inhibitors. Nat. Med. 19, 1401-1409 (2013).
-
(2013)
Nat. Med.
, vol.19
, pp. 1401-1409
-
-
Lito, P.1
Rosen, N.2
Solit, D.B.3
-
74
-
-
78049426513
-
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
-
Choi, Y. L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010).
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 1734-1739
-
-
Choi, Y.L.1
-
75
-
-
84925229458
-
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
-
Eirew, P. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422-426 (2015).
-
(2015)
Nature
, vol.518
, pp. 422-426
-
-
Eirew, P.1
-
76
-
-
84906238686
-
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
-
Wang, Y. et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155-160 (2014).
-
(2014)
Nature
, vol.512
, pp. 155-160
-
-
Wang, Y.1
-
77
-
-
84921433851
-
Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1
-
Kosaka, K. et al. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J. Viral. Hepat. 22, 158-165 (2015).
-
(2015)
J. Viral. Hepat.
, vol.22
, pp. 158-165
-
-
Kosaka, K.1
-
78
-
-
84906890825
-
Capturing intra-tumour genetic heterogeneity by de novo mutation profiling of circulating cell-free tumour DNA: A proof-of-principle
-
De Mattos-Arruda, L. et al. Capturing intra-tumour genetic heterogeneity by de novo mutation profiling of circulating cell-free tumour DNA: a proof-of-principle. Ann. Oncol. 25, 1729-1735 (2014).
-
(2014)
Ann. Oncol.
, vol.25
, pp. 1729-1735
-
-
De Mattos-Arruda, L.1
-
79
-
-
32944457518
-
MTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt
-
O'Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
-
(2006)
Cancer Res.
, vol.66
, pp. 1500-1508
-
-
O'Reilly, K.E.1
-
80
-
-
80053525113
-
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumours
-
Atzori, F. et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumours. Clin. Cancer Res. 17, 6304-6312 (2011).
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 6304-6312
-
-
Atzori, F.1
-
81
-
-
84886411678
-
Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer
-
Chen, X. et al. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. Mol. Cancer Res. 11, 1269-1278 (2013).
-
(2013)
Mol. Cancer Res.
, vol.11
, pp. 1269-1278
-
-
Chen, X.1
-
82
-
-
84861726854
-
-
ClinicalTrials.gov [online]
-
US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT02129556 (2015).
-
(2015)
US National Library of Medicine
-
-
-
83
-
-
84863078767
-
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
-
Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 520-529
-
-
Baselga, J.1
-
84
-
-
84861726854
-
-
ClinicalTrials.gov [online]
-
US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT01953926 (2015).
-
(2015)
US National Library of Medicine
-
-
-
85
-
-
84924571685
-
Neratinib (N) with or without temsirolimus (TEM) in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2 somatic mutations: An international randomized phase II study [abstract]
-
Besse, B. et al. Neratinib (N) with or without temsirolimus (TEM) in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2 somatic mutations: an international randomized phase II study [abstract]. Ann. Oncol. 25, LBA39 (2014).
-
(2014)
Ann. Oncol.
, vol.25
, pp. LBA39
-
-
Besse, B.1
-
86
-
-
84922389894
-
VE-BASKET a first-in-kind phase II histology-independent basket" study of vemurafenib (VEM) in nonmelanoma solid tumours harbouring BRAF V600 mutations (V600m) [abstract]
-
Hyman, D. M. et al. VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumours harbouring BRAF V600 mutations (V600m) [abstract]. J. Clin. Oncol. 32 (Suppl. 5), a2533 (2014).
-
(2014)
J. Clin. Oncol.
, vol.32
, pp. a2533
-
-
Hyman, D.M.1
-
87
-
-
84948387181
-
-
US National Library of Medicine ClinicalTrials.gov [online]
-
US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT02034981 (2015).
-
(2015)
-
-
-
88
-
-
84927177712
-
The AURORA initiative for metastatic breast cancer
-
Zardavas, D. et al. The AURORA initiative for metastatic breast cancer. Br. J. Cancer 111, 1881-1887 (2014).
-
(2014)
Br. J. Cancer
, vol.111
, pp. 1881-1887
-
-
Zardavas, D.1
-
89
-
-
84861726854
-
-
ClinicalTrials.gov [online]
-
US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT02154490 (2015).
-
(2015)
US National Library of Medicine
-
-
-
90
-
-
84884407337
-
Tumour heterogeneity in the clinic
-
Bedard, P. L., Hansen, A. R., Ratain, M. J., Siu, L. L. Tumour heterogeneity in the clinic. Nature 501, 355-364 (2013).
-
(2013)
Nature
, vol.501
, pp. 355-364
-
-
Bedard, P.L.1
Hansen, A.R.2
Ratain, M.J.3
Siu, L.L.4
-
91
-
-
79957857433
-
The BATTLE trial: Personalizing therapy for lung cancer
-
Kim, E. S. et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 1, 44-53 (2011).
-
(2011)
Cancer Discov.
, vol.1
, pp. 44-53
-
-
Kim, E.S.1
-
92
-
-
84921771510
-
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
-
Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33, 244-250 (2015).
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 244-250
-
-
Kaufman, B.1
-
93
-
-
84904121066
-
Cancer therapy Ex vivo culture of circulating breast tumour cells for individualized testing of drug susceptibility
-
Yu, M. et al. Cancer therapy. Ex vivo culture of circulating breast tumour cells for individualized testing of drug susceptibility. Science 345, 216-220 (2014).
-
(2014)
Science
, vol.345
, pp. 216-220
-
-
Yu, M.1
-
94
-
-
84880312534
-
Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies
-
Singh, V. M. et al. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann. Diagn. Pathol. 17, 322-326 (2013).
-
(2013)
Ann. Diagn. Pathol.
, vol.17
, pp. 322-326
-
-
Singh, V.M.1
-
95
-
-
84861726854
-
-
ClinicalTrials.gov [online]
-
US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT02299999 (2014).
-
(2014)
US National Library of Medicine
-
-
-
96
-
-
84861726854
-
-
ClinicalTrials.gov [online]
-
US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT01827384 (2015).
-
(2015)
US National Library of Medicine
-
-
-
97
-
-
84861726854
-
-
ClinicalTrials.gov [online]
-
US National Library of Medicine. ClinicalTrials.gov [online], https://www.clinicaltrials.gov/ct2/show/NCT01856296 (2013).
-
(2013)
US National Library of Medicine
-
-
|